Vertex Pharmaceuticals Beheer

Beheer criteriumcontroles 2/4

De CEO Vertex Pharmaceuticals is Reshma Kewalramani, benoemd in Apr2020, heeft een ambtstermijn van 4.58 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 20.59M, bestaande uit 7.3% salaris en 92.7% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.029% van de aandelen van het bedrijf, ter waarde $ 33.94M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 5.1 jaar en 4.8 jaar.

Belangrijke informatie

Reshma Kewalramani

Algemeen directeur

US$20.6m

Totale compensatie

Percentage CEO-salaris	7.3%
Dienstverband CEO	4.6yrs
Eigendom CEO	0.03%
Management gemiddelde ambtstermijn	5.1yrs
Gemiddelde ambtstermijn bestuur	4.8yrs

Recente managementupdates

Recent updates

Vertex Pharmaceuticals: Strong Execution Continued In Q3 But The Valuation Reflects It

Nov 05

Vertex Pharmaceuticals: Is The Recent Barclays Downgrade Justified? I'm Not Convinced

Sep 05

Vertex Stock: Came For CF Drugs, Staying For Gene Therapy

Aug 02

Is There An Opportunity With Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) 28% Undervaluation?

Jul 11

Vertex: Strategic Diversification From Gene Therapy To Acute Pain Management

Jul 09

If EPS Growth Is Important To You, Vertex Pharmaceuticals (NASDAQ:VRTX) Presents An Opportunity

Jun 20

Vertex: New, Longer-Term Casgevy Data Makes Case For Blockbuster Sales

Jun 17

Vertex: Like A Fine Wine, This Stock Seems To Get Better With Time

Jun 04

Here's Why Shareholders Will Not Be Complaining About Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) CEO Pay Packet

May 09

Vertex Pharmaceuticals Incorporated Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

May 08

Vertex To Buy Alpine Immune - Why This Deal Feels Slightly 'Vanilla'

Apr 11

Getting In Cheap On Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Is Unlikely

Apr 05

Vertex Pharmaceuticals: Diversifying Its Drug Portfolio For Future Growth

Mar 21

Are Investors Undervaluing Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) By 35%?

Mar 15

Vertex: One Of My All-Time Favorite Biotech Stocks Has More Room To Run

Feb 28

We Like The Quality Of Vertex Pharmaceuticals' (NASDAQ:VRTX) Earnings

Feb 22

Earnings Update: Here's Why Analysts Just Lifted Their Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Price Target To US$452

Feb 07

Vertex And Crispr: Second Casgevy Approval Pushes Revenue Potential Into Multi-Billion Dollar Range

Jan 22

With EPS Growth And More, Vertex Pharmaceuticals (NASDAQ:VRTX) Makes An Interesting Case

Jan 15

Risks To Shareholder Returns Are Elevated At These Prices For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Dec 25

An Intrinsic Calculation For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Suggests It's 29% Undervalued

Nov 13

With EPS Growth And More, Vertex Pharmaceuticals (NASDAQ:VRTX) Makes An Interesting Case

Oct 02

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Could Be 21% Below Their Intrinsic Value Estimate

Jul 31

We Ran A Stock Scan For Earnings Growth And Vertex Pharmaceuticals (NASDAQ:VRTX) Passed With Ease

Jul 03

Analyse CEO-vergoeding

Hoe is Reshma Kewalramani's beloning veranderd ten opzichte van Vertex Pharmaceuticals's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$480m
Jun 30 2024	n/a	n/a	-US$490m
Mar 31 2024	n/a	n/a	US$4b
Dec 31 2023	US$21m	US$2m	US$4b
Sep 30 2023	n/a	n/a	US$3b
Jun 30 2023	n/a	n/a	US$3b
Mar 31 2023	n/a	n/a	US$3b
Dec 31 2022	US$16m	US$1m	US$3b
Sep 30 2022	n/a	n/a	US$3b
Jun 30 2022	n/a	n/a	US$3b
Mar 31 2022	n/a	n/a	US$2b
Dec 31 2021	US$15m	US$1m	US$2b
Sep 30 2021	n/a	n/a	US$2b
Jun 30 2021	n/a	n/a	US$2b
Mar 31 2021	n/a	n/a	US$3b
Dec 31 2020	US$9m	US$1m	US$3b
Sep 30 2020	n/a	n/a	US$3b
Jun 30 2020	n/a	n/a	US$2b
Mar 31 2020	n/a	n/a	US$2b
Dec 31 2019	US$7m	US$702k	US$1b

Compensatie versus markt: De totale vergoeding ($USD 20.59M ) Reshma } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 12.73M ).

Compensatie versus inkomsten: De vergoeding van Reshma is gestegen terwijl het bedrijf verliesgevend is.

CEO

Reshma Kewalramani (51 yo)

4.6yrs

Tenure

US$20,594,441

Compensatie

Dr. Reshma Kewalramani, M.D., FASN, is Director at Year Up Inc. since September 2023. She had been an Independent Director of Ginkgo Bioworks Holdings, Inc. (formerly known as Ginkgo Bioworks, Inc.) since...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Jeffrey Leiden	Executive Chairman	15.3yrs	US$6.60m	0.0040% $ 4.7m
Reshma Kewalramani	CEO, President & Director	4.6yrs	US$20.59m	0.029% $ 33.9m
Charles Wagner	Executive VP & CFO	5.6yrs	US$7.37m	0.017% $ 19.8m
Stuart Arbuckle	Executive VP & COO	3.3yrs	US$9.00m	0.019% $ 22.3m
David Altshuler	Executive VP & Chief Scientific Officer	9.8yrs	US$6.54m	0.010% $ 11.6m
Kristen Ambrose	Senior VP & Chief Accounting Officer	3.5yrs	geen gegevens	0.0029% $ 3.4m
Mike Tirozzi	SVP and Chief Information & Data Officer	5.8yrs	geen gegevens	geen gegevens
Susie Lisa	Senior Vice President of Investor Relations	2.2yrs	geen gegevens	geen gegevens
Jonathan Biller	Executive VP & Chief Legal Officer	2.2yrs	geen gegevens	0.0065% $ 7.5m
Nina Devlin	Senior VP & Chief Communications Officer	5.8yrs	geen gegevens	geen gegevens
Stephanie Franklin	Senior VP & Chief Human Resources Officer	7.3yrs	geen gegevens	geen gegevens
Amit Sachdev	Executive VP & Chief Patient and External Affairs Officer	17.3yrs	US$6.20m	0.023% $ 26.1m

5.1yrs

Gemiddelde duur

57yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van VRTX is doorgewinterd en ervaren (gemiddelde ambtstermijn van 5.1 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Jeffrey Leiden	Executive Chairman	15.3yrs	US$6.60m	0.0040% $ 4.7m
Reshma Kewalramani	CEO, President & Director	4.8yrs	US$20.59m	0.029% $ 33.9m
Bruce Sachs	Lead Independent Director	26.8yrs	US$600.04k	0.016% $ 17.9m
Alan Garber	Independent Director	7.4yrs	US$537.63k	0.0023% $ 2.6m
Lloyd Carney	Independent Director	5.8yrs	US$559.79k	0.0021% $ 2.4m
Sangeeta Bhatia	Independent Director	9.4yrs	US$550.31k	0.0013% $ 1.5m
Michel Lagarde	Independent Director	1.1yrs	US$449.08k	geen gegevens
Diana McKenzie	Independent Director	4.4yrs	US$553.11k	0.00064% $ 738.4k
Suketu Upadhyay	Independent Director	2.5yrs	US$544.66k	0.00060% $ 692.3k
Nancy Thornberry	Independent Director	less than a year	US$407.65k	geen gegevens
Jennifer Schneider	Independent Director	less than a year	geen gegevens	geen gegevens

4.8yrs

Gemiddelde duur

59yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van VRTX wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.8 jaar).

Vertex Pharmaceuticals Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

CEO, President & Director notifies of intention to sell stock

Executive VP & Chief Legal Officer notifies of intention to sell stock

Executive Chairman notifies of intention to sell stock

CEO, President & Director notifies of intention to sell stock

CEO, President & Director notifies of intention to sell stock

CEO, President & Director notifies of intention to sell stock

Recent updates

CEO, President & Director notifies of intention to sell stock

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Vertex Pharmaceuticals: Strong Execution Continued In Q3 But The Valuation Reflects It

Vertex Pharmaceuticals Incorporated Raises Earnings Guidance for the Full Year 2024

Vertex Pharmaceuticals: The Future Looks Bright, But It May Be A Choppy Ride

Vertex Pharmaceuticals Incorporated to Report Q3, 2024 Results on Nov 04, 2024

Vertex Joined The M&A Craze - Limited Upside Potential (Downgrade)

Executive VP & Chief Legal Officer notifies of intention to sell stock

Investors Are Underestimating The Potential Of Vertex's Non-Addictive Pain Drug

Vertex Pharmaceuticals: Is The Recent Barclays Downgrade Justified? I'm Not Convinced

Executive Chairman notifies of intention to sell stock

Second quarter 2024 earnings: EPS misses analyst expectations

Vertex Pharmaceuticals Incorporated Raises Earnings Guidance for the Full Year 2024

Vertex Stock: Came For CF Drugs, Staying For Gene Therapy

CEO, President & Director notifies of intention to sell stock

Vertex Pharmaceuticals Incorporated Announces FDA Acceptance of New Drug Application for Suzetrigine for the Treatment of Moderate-To-Severe Acute Pain

CEO, President & Director notifies of intention to sell stock

Consensus EPS estimates fall by 12%

Vertex Pharmaceuticals Incorporated Announces Health Canada Grants Marketing Authorization for Trikafa® for People with Cystic Fibrosis Aged 2 Years and Older with Certain Rare Mutations

Is There An Opportunity With Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) 28% Undervaluation?

Vertex: Strategic Diversification From Gene Therapy To Acute Pain Management

Vertex Pharmaceuticals Incorporated to Report Q2, 2024 Results on Aug 01, 2024

Vertex Pharmaceuticals, Inc. Announces Positive Results from Ongoing Phase 1/2 Study of VX-880 for the Treatment of Type 1 Diabetes

If EPS Growth Is Important To You, Vertex Pharmaceuticals (NASDAQ:VRTX) Presents An Opportunity

Vertex: New, Longer-Term Casgevy Data Makes Case For Blockbuster Sales

Vertex: Like A Fine Wine, This Stock Seems To Get Better With Time

CEO, President & Director notifies of intention to sell stock

Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) completed the acquisition of Alpine Immune Sciences, Inc. (NasdaqGM:ALPN) from a group of shareholders.

Vertex Pharmaceuticals Incorporated Appoints Jennifer Schneider as Independent Director

Here's Why Shareholders Will Not Be Complaining About Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) CEO Pay Packet

Vertex Pharmaceuticals Incorporated Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Vertex Pharmaceuticals Incorporated Re-Iterates Earnings Guidance for the Full Year 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Vertex Pharmaceuticals Announces European Commission Approval for KALYDECO to Treat Infants with Cystic Fibrosis Ages 1 Month and Older

Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) entered into an agreement to acquire Alpine Immune Sciences, Inc. (NasdaqGM:ALPN) from a group of shareholders for approximately $4.3 billion.

Vertex To Buy Alpine Immune - Why This Deal Feels Slightly 'Vanilla'

Vertex Pharmaceuticals Incorporated to Report Q1, 2024 Results on May 06, 2024

Vertex Pharmaceuticals Incorporated, Annual General Meeting, May 15, 2024

Getting In Cheap On Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Is Unlikely

Vertex Pharmaceuticals Incorporated Announces New Drug Submission for Exagamglogene Autotemcel (Exa-Cel) Accepted for Priority Review by Health Canada for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

Vertex Pharmaceuticals: Diversifying Its Drug Portfolio For Future Growth

Are Investors Undervaluing Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) By 35%?

Vertex: One Of My All-Time Favorite Biotech Stocks Has More Room To Run

Vertex Pharmaceuticals Receives CHMP Positive Opinion for KALYDECO for the Treatment of Infants with Cystic Fibrosis Ages 1 Month and Older

We Like The Quality Of Vertex Pharmaceuticals' (NASDAQ:VRTX) Earnings

Executive VP & COO notifies of intention to sell stock

European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

Vertex Pharmaceuticals Incorporated Announces Positive Results from Pivotal Trials of Vanza Triple Combination Treatment for Cystic Fibrosis

Earnings Update: Here's Why Analysts Just Lifted Their Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Price Target To US$452

Full year 2023 earnings: EPS exceeds analyst expectations

Vertex Pharmaceuticals Incorporated Provides Product Revenue Guidance for the Full Year 2024

Vertex Announces Positive Results from the VX-548 Phase 3 Program for the Treatment of Moderate-To-Severe Acute Pain

Vertex And Crispr: Second Casgevy Approval Pushes Revenue Potential Into Multi-Billion Dollar Range

Vertex Pharmaceuticals Incorporated to Report Q4, 2023 Results on Feb 05, 2024

Vertex Pharmaceuticals Incorporated Announces US FDA Approval of CASGEVY™ (Exagamglogene Autotemcel) for the Treatment of Transfusion-Dependent Beta Thalassemia

With EPS Growth And More, Vertex Pharmaceuticals (NASDAQ:VRTX) Makes An Interesting Case

Vertex Pharmaceuticals Incorporated Announces Approval of First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™, for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Kingdom of Saudi

Executive VP & CFO notifies of intention to sell stock

Risks To Shareholder Returns Are Elevated At These Prices For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Executive Chairman notifies of intention to sell stock

Vertex Pharmaceuticals Incorporated Receives CHMP Positive Opinion for the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY (Exagamglogene Autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

Vertex Pharmaceuticals Incorporated Announces Positive Results From Phase 2 Study of VX-548 for the Treatment of Painful Diabetic Peripheral Neuropathy

CRISPR Therapeutics AG and Vertex Pharmaceuticals Incorporated Announce Receipt of the First-Ever Approval of a CRISPR-Based Gene-editing Therapy in the United States

Vertex Pharmaceuticals Incorporated Appoints Nancy Thornberry to Its Board of Directors as an Independent Director

Health Canada Grants Market Authorization for KALYDECO® (ivacaftor) for Eligible Children With Cystic Fibrosis Ages 2 Months and Older

Vertex Pharmaceuticals Incorporated Announces European Commission Approves KAFTRIO® in Combination With Ivacaftor for the Treatment of Children With Cystic Fibrosis Ages 2 Through 5

Vertex Pharmaceuticals Incorporated Announces United Kingdom Medicines and Healthcare Products Regulatory Agency Granted Conditional Marketing Authorization for CASGEVY

An Intrinsic Calculation For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Suggests It's 29% Undervalued

Lead Independent Director notifies of intention to sell stock